Agreements reached under this partnership
Business alliance- 1
Optimization of virtual screening methods and drug discovery workflows
- 2
Establishment of rational compound design guidelines based on binding free-energy evaluation
- 3
Advancement of compound design methods using generative AI for molecular structures
- 4
Verification of computational results by comparison with experimental data, with ongoing evaluation of their practical applicability to drug discovery research
These are items that the documents state the two companies will work on. The lines above and below represent arrangements between the two companies.
The impact of this matter on consolidated full-year results for the fiscal year ending December 2026 is expected to be minor, and there is no change to the consolidated full-year earnings forecast for the fiscal year ending December 2026 announced on 13 February 2026. Over the medium to long term, the Company expects this agreement to strengthen its research and development portfolio and expand its development pipeline.
| Item | Details |
|---|---|
| Name of alliance partner | RIKEN, a national research and development agency |
| Alliance partner's business activities | Development of an in silico drug discovery platform integrating molecular dynamics calculations and quantum chemical calculations with AI, and molecular design and screening research for a wide range of drug discovery targets |
| Alliance partner's location | Wako City, Saitama Prefecture |
| Type of alliance | Business alliance |
| Details of the alliance | Optimization of virtual screening methods and drug discovery workflows, Establishment of rational compound design guidelines based on binding free-energy evaluation, Advancement of compound design methods using generative AI for molecular structures, Verification of computational results by comparison with experimental data, with ongoing evaluation of their practical applicability to drug discovery research |
| Contract Date | 2 June 2026 |
| Impact on Business Performance | The impact of this matter on consolidated full-year results for the fiscal year ending December 2026 is expected to be minor, and there is no change to the consolidated full-year earnings forecast for the fiscal year ending December 2026 announced on 13 February 2026. Over the medium to long term, the Company expects this agreement to strengthen its research and development portfolio and expand its development pipeline. |
Items this document does not state (16)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The agreement is intended to improve and advance the efficiency of drug discovery research, establish new drug discovery support technologies, and strengthen research and development capabilities. The impact on consolidated full-year results for the fiscal year ending December 2026 is expected to be minor, and there is no change to the previously announced earnings forecast.